Assessment of chemotherapy-induced cognitive impairment in cancer patients

Authors

  • Vaishnavi Prasannan Department of Pharmacy Practice, Acharya and B. M. Reddy College of Pharmacy, Soldevanahalli, Achit Nagar, Bengaluru, Karnataka, India
  • Joseph Joseph Department of Pharmacy Practice, Acharya and B. M. Reddy College of Pharmacy, Soldevanahalli, Achit Nagar, Bengaluru, Karnataka, India
  • Sibu S. Teli Department of Pharmacy Practice, Acharya and B. M. Reddy College of Pharmacy, Soldevanahalli, Achit Nagar, Bengaluru, Karnataka, India
  • Simab Akhtar Department of Pharmacy Practice, Acharya and B. M. Reddy College of Pharmacy, Soldevanahalli, Achit Nagar, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20263540

Keywords:

Chemotherapy-induced cognitive impairment, Cancer, FACT-Cog, Cognitive function, Chemotherapy

Abstract

Background: Chemotherapy-induced cognitive impairment (CICI) is a well-established side-effect of cancer treatment, which can impact memory, attention, executive function and quality of life. There have been reports of cognitive impairment in chemotherapy-treated patients, but there is limited data in the Indian population. This study was conducted to assess the prevalence of CICI and identify factors associated with cognitive impairment among patients undergoing chemotherapy.

Methods: A cross-sectional observational study was performed among 160 adult cancer patients receiving chemotherapy treatment at a tertiary care center. The functional assessment of cancer therapy – cognitive function (FACT-Cog, version 3) questionnaire was used to measure cognitive function. A structured case record form was used to gather the demographic and clinical information. Descriptive statistics, correlation analysis and multivariable logistic regression were used for statistical analysis to find independent predictors of cognitive impairment.

Results: Among 160 participants, 57 (35.6%) had chemotherapy induced cognitive impairment. Cognitive function was significantly associated with advanced cancer stage and number of chemotherapy cycles and was an independent predictor of cognitive impairment in multivariable analyses. Type 2 diabetes mellitus was associated with lower odds of cognitive impairment, although this finding requires further investigation.

Conclusions: Cognitive impairment was common among patients who were receiving chemotherapy. Greater treatment exposure and advanced disease stage were independently associated with cognitive impairment, highlighting the importance of routine cognitive assessment during cancer treatment. Further prospective multicenter studies are needed to confirm these findings and improve the management of chemotherapy-induced cognitive impairment.

Metrics

Metrics Loading ...

References

Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discov Oncol. 2025;16(1):607. DOI: https://doi.org/10.1007/s12672-025-02198-8

Das A, Ranadive N, Kinra M, Nampoothiri M, Arora D, Mudgal J. An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants. Curr Neuropharmacol. 2020;18(9):838-51. DOI: https://doi.org/10.2174/1570159X18666200221113842

Neth BJ, Schagen SB, Wefel JS. Cancer treatment-related cognitive impairment. Neurooncol Adv. 2026;8(Suppl 5):37-57. DOI: https://doi.org/10.1093/noajnl/vdag064

Cheung YT, Ho MH, Fardell J, Vardy JL. Assessment and management of cancer-related cognitive impairment. Am Soc Clin Oncol Educ Book. 2026;46(3):e517676. DOI: https://doi.org/10.1200/EDBK-26-517676

Fleming B, Edison P, Kenny L. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ. 2023;380:e071726. DOI: https://doi.org/10.1136/bmj-2022-071726

Van Dyk K, Crespi CM, Petersen L, Ganz PA. Identifying cancer-related cognitive impairment using the FACT-Cog Perceived Cognitive Impairment. JNCI Cancer Spectr. 2020;4(1):pkz099. DOI: https://doi.org/10.1093/jncics/pkz099

Singh P, Leon C, Kaur S, Batra A, Tayade P, Prakash MS, et al. Acute and long-term effects of chemotherapy on cognitive function among Indian breast cancer patients. Ecancermedicalscience. 2025;19:1856. DOI: https://doi.org/10.3332/ecancer.2025.1856

Kim HJ, Jung SO, Kim H, Abraham I. Systematic review of longitudinal studies on chemotherapy-associated subjective cognitive impairment in cancer patients. Psychooncology. 2020;29(4):617-31. DOI: https://doi.org/10.1002/pon.5339

Janelsins MC, Heckler CE, Peppone LJ, Ahles TA, Mohile SG, Mustian KM, et al. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. J Clin Oncol. 2018;36(32):JCO2018786624. DOI: https://doi.org/10.1200/JCO.2018.78.6624

Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18(14):2695-701. DOI: https://doi.org/10.1200/JCO.2000.18.14.2695

Whittaker AL, George RP, O'Malley L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis. Sci Rep. 2022;12(1):2135. DOI: https://doi.org/10.1038/s41598-022-05682-1

Maurer GS, Clayton ZS. Anthracycline chemotherapy, vascular dysfunction and cognitive impairment: burgeoning topics and future directions. Future Cardiol. 2023;19(11):547-66. DOI: https://doi.org/10.2217/fca-2022-0086

Durán-Gómez N, López-Jurado CF, Nadal-Delgado M, Pérez-Civantos D, Guerrero-Martín J, Cáceres MC. Chemotherapy-Related Cognitive Impairment in Patients with Breast Cancer Based on Functional Assessment and NIRS Analysis. J Clin Med. 2022;11(9):2363. DOI: https://doi.org/10.3390/jcm11092363

Root JC, Zhou X, Ahn J, Small BJ, Zhai W, Bethea T, et al. Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study. Breast Cancer Res Treat. 2022;194(2):413-22. DOI: https://doi.org/10.1007/s10549-022-06623-2

Areosa Sastre A, Vernooij RW, González-Colaço Harmand M, Martínez G. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6(6):CD003804. DOI: https://doi.org/10.1002/14651858.CD003804.pub2

Tabesh M, Sacre JW, Mehta K, Chen L, Sajjadi SF, Magliano DJ, et al. Associations of glycaemia-related risk factors with dementia and cognitive decline in individuals with type 2 diabetes: A systematic review and meta-analysis. Diabet Med. 2025;42:e70123. DOI: https://doi.org/10.1111/dme.70123

Downloads

Published

2026-09-29

How to Cite

Prasannan, V., Joseph, J., Teli, S. S., & Akhtar , S. (2026). Assessment of chemotherapy-induced cognitive impairment in cancer patients. International Journal of Research in Medical Sciences, 14(10), 4674–4680. https://doi.org/10.18203/2320-6012.ijrms20263540

Issue

Section

Original Research Articles